METHOD FOR INACTIVATING A PRION PROTEIN

• US 20160089422A1
• Filed: 05/15/2014
• Published: 03/31/2016
• Est. Priority Date: 05/15/2013
• Status: Abandoned Application

• Current Assignee: Laboratoire francais du Fractionnement et des Biotechnologies
• Original Assignee: Laboratoire francais du Fractionnement et des Biotechnologies
• Inventors: Chtourou, Abdessatar Sami, Flan, Benot
• Application Number:
  US14/891,139
• Publication Number:
  US 20160089422A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)

Abstract

The invention relates to a process for inactivating pathological prion proteins (PrPsc) in a sample or a material which may be contaminated by a pathological prion protein, wherein the sample or the material which may be contaminated by a pathological prion protein is put into contact with at least one methionine sulfoxide reductase.

Claims

1. A process for inactivating pathological prion proteins (PrPsc) in a sample or a material which may be contaminated by a pathological prion protein, wherein the sample or the material which may be contaminated by a pathological prion protein is put into contact with at least one methionine sulfoxide reductase (MSR).

2. The inactivation process according to claim 1, wherein the methionine sulfoxide reductase is a human MSR.

3. The inactivation process according to claim 1, wherein the methionine sulfoxide reductase is a methionine sulfoxide reductase A (MSRA).

4. The inactivation process according to claim 1, wherein the methionine sulfoxide reductase is a methionine sulfoxide reductase B (MSRB).

5. The inactivation process according to claim 1, wherein the methionine sulfoxide reductase is of natural origin.

6. The inactivation process according to claim 1, wherein the methionine sulfoxide reductase is of synthetic origin.

7. The inactivation process according to claim 1, wherein the methionine sulfoxide reductase was produced by genetic recombination.

8. The inactivation process according to claim 1, wherein the sample which may be contaminated by a pathological prion protein is a biological product.

9. The inactivation process according to claim 1, wherein the step for inactivating pathological prion proteins with MSR is conducted at a temperature below 60°

C.

10. The inactivation process according to claim 1, further comprising a step for heat treatment of the sample or material which may be contaminated by a pathological prion protein, at a temperature above 60°

C., before or after the step for inactivating the pathological prion proteins with MSR.

11. The inactivation process according to claim 1, comprising the addition of NADH or NADPH to the sample or material which may be contaminated by a pathological prion protein.

12. The inactivation process according to claim 1, wherein the MSR is immobilized on a solid support.

13. The inactivation process according to claim 8, wherein the sample which may be contaminated by a pathological prion protein is a blood product.

14. The inactivation process according to claim 13, wherein the sample which may be contaminated by a pathological prion protein is plasma or a plasma product.

15. The inactivation process according to claim 12, wherein the MSR is immobilized on the solid support by a covalent bond.

16. The inactivation process according to claim 15, wherein the MSR is immobilized on the solid support by simple cross-linking.